NeoGenomics (NEO) Tops Q1 EPS by 10c; Guides for FY16 Adjusted Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains
April 27, 2016 7:00 AM EDTFT. MYERS, Fla., April 27, 2016 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2016.
First Quarter 2016 Highlights:
159% increase in consolidated revenue to a record $59.7 million 442% increase in consolidated Adjusted EBITDA(1) to record $8.2 million 175% increase in consolidated clinical genetic testing volume(2) Adjusted Diluted EPS(1) of $0.03 per share and Diluted EPS of ($0.07) per shareConsolidated Revenue for the fourth quarter was $59.7... More
